Battino D, Cusi C, Franceschetti S, Moise A, Spina S, Avanzini G
Clin Pharmacokinet. 1982 Mar-Apr;7(2):176-80. doi: 10.2165/00003088-198207020-00006.
The relationship between oral dose and plasma concentration of ethosuximide was evaluated retrospectively in 198 epileptic patients aged 2.5 to 34 years. Age appears to be a major factor in determining the ethosuximide plasma level/dose (L/D) ratio. Children younger than 10 years had men L/D ratios significantly lower (p less than 0.0003) than adolescents (10 to 15 years of age) and adults (16 to 34 years of age). Associated antiepileptic therapy reduced the ethosuximide L/D ratio: mean ethosuximide L/D ratios were significantly lower in patients also taking primidone (p less than 0.0005) or valproic acid (p less than 0.02). The correlation between the dose of ethosuximide administered and the plasma concentration was significant in the 3 age groups considered (p less than 0.0004), but the wide scattering of individual plasma concentrations makes it impossible to predict what plasma concentration of ethosuximide will be obtained after a given dose. For this reason, routine monitoring of ethosuximide plasma concentrations still appears to be necessary, especially in children and patients on polytherapy.
对198名年龄在2.5至34岁之间的癫痫患者进行了回顾性评估，以研究乙琥胺口服剂量与血浆浓度之间的关系。年龄似乎是决定乙琥胺血浆水平/剂量（L/D）比的主要因素。10岁以下儿童的L/D比值显著低于青少年（10至15岁）和成年人（16至34岁）（p<0.0003）。联合抗癫痫治疗会降低乙琥胺的L/D比值：同时服用扑米酮（p<0.0005）或丙戊酸（p<0.02）的患者，乙琥胺的平均L/D比值显著更低。在所研究的三个年龄组中，乙琥胺给药剂量与血浆浓度之间的相关性均显著（p<0.0004），但个体血浆浓度的广泛离散使得无法预测给予特定剂量后乙琥胺的血浆浓度。因此，常规监测乙琥胺血浆浓度似乎仍然必要，尤其是在儿童和接受联合治疗的患者中。
